Follow The Filings

EMBC Embecta Corporation

Health Care, filed as Embecta Corp (COM), Equity As of 2026 Q2 among managers we track Quote on Google Finance, opens in a new tab

Bought by 2 managers in 2026 Q2, sold by 1

  • 2 Owners
  • Max 1.4%
  • $18M
  • 2 add 1 exit

In 2026 Q2 Michael Krensavage and Don Yacktman added to Embecta, while Tweedy, Browne Co. sold out.

Who owns this now

Largest portfolio weights among holders, up to 1.4% (Michael Krensavage, Krensavage Asset Management). Not free-float ownership.

  1. Michael Krensavage Add 1.4%
  2. Don Yacktman Add 0.17%

Who owns EMBC

Sorted by value, long equity only, as of 2026 Q2.

History
Don Yacktman, Yacktman Asset Management 0.17% Add +17.5% 4,315,952 $14M History
Michael Krensavage, Krensavage Asset Management 1.4% Add +54.4% 1,135,340 $3.7M History
Tweedy, Browne Co. exited 2026 Q2 Last 2026 Q1 0.05% Exit −0.05% 75,356 $666K History

2 current, 1 exited last period, options excluded

Weight bar: held both quarters added sold at this quarter’s reported price

Insider trades

Open-market buys and sales by EMBC's executives, directors and 10% owners in the last 12 months, from their Form 4s

All EMBC insider trades
  • $558K bought by 4 insiders
  • $37K sold by 1 insider outside a trading plan
  • None no planned (10b5-1) sales
  1. Milton Mayo Morris Director
    Sale
    $37K 6,293 shares at $5.88 11% of stake
    Traded Sep 4 Filed Sep 8
    ↗
  2. Devdatt Kurdikar CEO
    Buy
    $141K 30,000 shares at $4.70 +3.9% to stake
    Traded Aug 12 Filed Aug 13
    ↗
  3. Jacob Elguicze CFO
    Buy
    $93K 20,000 shares at $4.67 +6.9% to stake
    Traded Aug 12 Filed Aug 13
    ↗
  4. Jeffrey Z Mann Pres, Pharm Svc&Prod Mgmt, CLO
    Buy
    $100K 20,000 shares at $4.99 +8.2% to stake
    Traded Aug 12 Filed Aug 13
    ↗
  5. Robert J. Hombach Director
    Buy
    $224K 45,000 shares at $4.97 +70% to stake
    Traded Aug 12 Filed Aug 13
    ↗

Also filed in the last 12 months, not counted as buying or selling: 17 stock grants and 7 share withholdings for taxes.

Congress

No member of Congress reported trading EMBC in the last three years. 2 members listed it in 2025 annual reports.

All Congress trades

SEC filings

Recent issuer filings from EDGAR, 21 shown.

Filed Form Detail Links
SCHEDULE 13G/A — Filing Doc
8-K 2.02,9.01 Filing Doc
10-Q Filing Doc
8-K/A 9.01 Filing Doc
SCHEDULE 13G/A — Filing Doc
SCHEDULE 13G/A — Filing Doc
8-K 2.01,7.01,9.01 Filing Doc
SCHEDULE 13G — Filing Doc
8-K 2.02,9.01 Filing Doc
10-Q Filing Doc
SCHEDULE 13G/A — Filing Doc
SCHEDULE 13G — Filing Doc
SCHEDULE 13G/A — Filing Doc
8-K 1.01,7.01,9.01 Filing Doc
8-K 5.07 Filing Doc
8-K 2.02,9.01 Filing Doc
10-Q Filing Doc
SCHEDULE 13G/A — Filing Doc
DEFA14A SCHEDULE 14A Filing Doc
DEF 14A Filing Doc
DEFA14A Filing Doc

Source: SEC EDGAR submissions, updated 5 days ago. All on EDGAR

Financials

US-GAAP annual figures by fiscal year, as tagged in Form 10-K. Each value links to its SEC filing.

Income statement

Metric FY2023 FY2024 FY2025
Revenue $1.12B $1.12B $1.08B
Gross profit $749.9M $735.2M $676.8M
Gross margin * 66.9% 65.5% 62.6%
Net income $70.4M $78.3M $95.4M
Net margin * 6.3% 7.0% 8.8%

Balance sheet

Metric FY2023 FY2024 FY2025
Total current assets $749.1M $761M $631.4M
Total non-current assets * $465.3M $524.3M $459.5M
Total assets $1.21B $1.29B $1.09B
Total current liabilities $353.5M $374M $261.5M
Total equity -$821.7M -$738.3M -$650.6M

Cash flow

Metric FY2023 FY2024 FY2025
Cash from operations $67.7M $35.7M $191.7M
Cash from investing -$26.5M -$15.8M -$9.3M
Cash from financing -$48.7M -$73.4M -$226.7M
Net change in cash -$4.4M -$52.3M -$45.6M

Source: SEC companyfacts (US-GAAP 10-K). A * marks a computed figure, not a single XBRL tag. Fiscal years are as the issuer labels them. Follow The Filings does not adjust or audit these figures.

Ownership over time

13Fs that reported it each quarter. Click a bar for that quarter’s holders.